Most Read Articles
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Roshini Claire Anthony, 07 Jun 2017

The addition of pertuzumab to standard-of-care therapy may convey a positive, albeit modest, effect for women with HER2-positive breast cancer, according to findings from the APHINITY* trial presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.

Jackey Suen, 30 Jun 2015
The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) have developed new approaches to assist oncologists in evaluating anticancer regimens available in the market.
16 Nov 2015
Difficulties in verbal fluency and comprehension were usually experienced by adolescents with Sydenham chorea, a study has shown.

Accelerated elozutumab infusion safe for multiple myeloma

08 Sep 2017

Accelerated administration of elotuzumab for multiple myeloma (MM) or relapsed/refractory MM (RRMM) is safe and produces no grade 3 or 4 infusion reactions (IRs), a phase 2 study shows.

Investigators involved 70 adults with active and newly diagnosed MM or RRMM (median age 67.5 years). Of these, 47 percent (n=33) had received prior treatments for MM, the most common of which was bortezomib (41 percent).

Infusion rate of the first dose of elotuzumab during cycle 1 was increased from 0.5 to 2 mL/min in the absence of IRs. Rates were increased from 3 to 4 mL/min during dose 2 and to mL/min for all succeeding doses. Of all infusions, 87 percent (n=968) were delivered at the maximum rate of 5 mL/min.

There were no reported cases of the primary outcome of grade 3 or 4 IRs by the end of cycle 2. Only two IRs were reported, both of which manifested during the 2 mL/min infusion rate. One patient experienced a nonspecific grade 2 infusion-related reaction, while the other had a grade 1 pyrexia.

Infusion was interrupted only in the case of the grade 2 IR but was resumed after resolution. No treatments were discontinued due to IRs.

The most common adverse event (AE) was infection which was observed in 60 percent (n=42) of the participants. This was followed by fatigue (50 percent; n=35) and diarrhoea (31 percent; n=22). Eight cases of grade 4 AEs were reported and 13 patients discontinued treatment because of AEs.

A total of 27 patients experienced severe AEs, the most common of which were pneumonia and atrial fibrillation which were observed in three patients each. There was a total of five deaths caused by disease progression, fatal bleeding, respiratory failure and ischaemic bowel syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Roshini Claire Anthony, 07 Jun 2017

The addition of pertuzumab to standard-of-care therapy may convey a positive, albeit modest, effect for women with HER2-positive breast cancer, according to findings from the APHINITY* trial presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.

Jackey Suen, 30 Jun 2015
The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) have developed new approaches to assist oncologists in evaluating anticancer regimens available in the market.
16 Nov 2015
Difficulties in verbal fluency and comprehension were usually experienced by adolescents with Sydenham chorea, a study has shown.